FindMyKOL
Clinical trialNCT00665470CompletedPhase 2Interventional

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

NCT00665470 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is completed. It studies Aldesleukin in Metastatic Melanoma and Skin Cancer. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2008 and a primary completion date of 30 Apr 2012.

SponsorNational Cancer Institute (NCI) →Enrollment10Metastatic MelanomaSkin Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00665470
FieldValue
Registry IDNCT00665470
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorNational Cancer Institute (NCI)
Enrollment10
Registered sites1
Countries1
ConditionsMetastatic Melanoma and Skin Cancer
DrugsAldesleukin
Start30 Apr 2008
Primary completion30 Apr 2012
Study completion30 Apr 2012
Last update posted19 Oct 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: This study uses a new experimental procedure for treating melanoma that uses the patient's own lymphocytes (type of white blood cell), which are specially selected to target and destroy their tumor. Objectives: To determine whether this experimental treatment can cause the patient's tumor to shrink. To test the safety of the treatment and its effects on the immune system. Eligibility: Patients with metastatic melanoma 18 years of age and older for whom standard treatments are not effective or who cannot take high-dose interleukin-2 (IL-2). Patients must have the tissue type human leukocyte antigens (HLA-A)0201. Design: Workup: Patients have scans, x-rays, laboratory tests, and other tests as needed. Patients have leukapheresis (a procedure for collecting lymphocytes that is similar to collecting whole blood) to collect cells for laboratory treatment and later reinfusion. Chemotherapy: Patients have low-dose chemotherapy for 1 week to prepare the immune system to receive the cultured lymphocytes. Cell infusion and IL-2 treatment: Patients receive the lymphocytes by infusion through a vein and then either high-dose IL-2 infused through a vein or low-dose IL-2 injected under the skin. High-dose IL-2 is given as infusions through a vein every 8 hours for up to 15 doses. Low-dose IL-2 is given as injections under the skin daily for 5 days, followed by a 2-day rest, with this regimen repeated for a total of 5 weeks. Recovery: Patients rest for 1 to 2 weeks to recover from the effects of chemotherapy and IL-2. Tumor biopsy: Patients may be asked to have a biopsy (removal of a small piece of tumor) after receiving treatment to look at the effects of treatment in the tumor. Follow-up: After treatment is completed, patients return to the clinic for physical examinations, review of side effects, laboratory tests and scans every 1 to 6 months until the disease worsens. Retreatment: Patients whose tumor did not grow after treatment or showed evidence of shrinking may be able to be retreated if their tumor begins to grow. They receive the same regimen of chemotherapy, lymphocyte infusion and IL-2 treatment....

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00665470

Each answer restates registry values shown on this page.

What is NCT00665470?

NCT00665470 is a phase 2 interventional trial sponsored by National Cancer Institute (NCI). It studies Aldesleukin in Metastatic Melanoma and Skin Cancer.

Who leads NCT00665470?

The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.

Where does NCT00665470 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00665470 study?

The registered drug and biological interventions are Aldesleukin.

When did NCT00665470 end?

The registry lists a primary completion date of 30 Apr 2012 and a study completion date of 30 Apr 2012. The sponsor last updated the record on 19 Oct 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.